Engflag

Tormina

Quick links to important sections

Tormina

Tormina_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tormina

Quick Facts

Property Description
Active Ingredients Dicyclomine, Paracetamol
Form Oral Tablet
Pharmacological Class Antispasmodic-Analgesic Combination
Origin Synthetic
Primary Action Relaxes smooth muscle and relieves general pain

What Type of Medicine is Tormina?

Tormina is a fixed-dose combination medicine administered via the oral tablet form, classified as an Antispasmodic-Analgesic Combination. Both of its active ingredients are synthetic compounds, designed to deliver two complementary therapeutic effects within a single preparation. This specific dual approach to symptomatic relief is intended for pains where muscle spasm is a core component. The drug's identity is rooted in its strategy of simultaneously addressing muscle contraction and general discomfort.

The Composition: Dicyclomine and Paracetamol

The formulation's active ingredients are Dicyclomine and Paracetamol. Dicyclomine functions as the antispasmodic component, belonging to the anticholinergic class, which acts by relaxing the smooth muscles of the gastrointestinal tract. Paracetamol provides the medicine's analgesic and antipyretic effects. Paracetamol is recognized for its general pain-relieving properties due to its central mechanism of action. This coupling ensures the drug addresses both the physical cause of the cramp and the resulting sensation of pain.

General Purpose of This Dual-Action Drug

The general purpose of this combination product is to provide symptomatic relief for painful cramping, such as the acute discomfort associated with intestinal colic or dysmenorrhea. By addressing both the muscular spasm and the general feeling of pain, the drug offers a consolidated approach to managing acute discomfort associated with contractions in internal organs. This dual action targets smooth muscle relaxation to ease the cramp and pain signal relief to mitigate the accompanying distress, providing a focused intervention for symptomatic management.

Regulatory References

  1. WHO Essential Medicines

What side effects are possible with Tormina?

Official Safety Profile and Adverse Reactions

Regulatory documents organize the safety profile of Tormina by classifying all reported adverse reactions based on their frequency and the affected body system. This structured approach helps in understanding the likelihood and nature of potential side effects.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized according to standard international frequency bands, ranging from very common to very rare.

Classification Estimated Frequency
Very Common Occurs in 1 in 10 people or more (ge 1/10)
Common Occurs in 1 to 10 in 100 people (ge 1/100 to < 1/10)
Uncommon Occurs in 1 to 10 in 1,000 people (ge 1/1,000 to < 1/100)
Rare Occurs in 1 to 10 in 10,000 people (ge 1/10,000 to < 1/1,000)
Very Rare Occurs in less than 1 in 10,000 people (< 1/10,000)
Not Known Frequency cannot be estimated from available data

Serious Adverse Reactions and Safety Restrictions

Official prescribing information highlights specific safety concerns and formal limitations on use. These are often grouped by the body system affected (System-Organ-Classes) such as gastrointestinal, nervous, or immune system disorders.

Serious Adverse Reactions (as documented in regulatory sources) include events that are life-threatening or require immediate medical intervention, such as severe allergic reactions (e.g., Anaphylaxis), significant liver damage, or severe blood disorders.

Safety-related restrictions include formal Contraindications, which are conditions under which Tormina must not be used (e.g., known hypersensitivity), and Warnings and Precautions, which detail circumstances requiring careful monitoring or risk assessment.

Population-Specific Safety Considerations

Regulatory labels provide explicit information regarding the use of Tormina in certain patient populations. This includes safety considerations and necessary monitoring for individuals with pre-existing conditions, such as severe kidney or liver impairment, as well as pregnant or breastfeeding women. These specific guidelines ensure that the risk-benefit profile is appropriately assessed for vulnerable groups.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Tormina, a combination of Dicyclomine and Paracetamol, presents a dual toxicity profile as documented by regulatory authorities. Immediate medical advice must be sought for any suspected overdose, even if the individual appears well, due to the critical risk of delayed, serious organ damage.

Documented Overdose Manifestations

Component Symptoms and Severe Outcomes
Paracetamol Early signs include nausea, vomiting, and pallor. Severe outcomes can involve fulminant hepatic failure, elevated liver enzymes, and acute renal failure, which may manifest 12 to 48 hours post-ingestion.
Dicyclomine Signs of anticholinergic toxicity include confusion, disorientation, dilated pupils, dry mouth, tachycardia, and palpitations. Severe cases may progress to coma or psychosis.

Emergency Actions Mandated by Regulators

Regulatory agencies require that the patient be urgently referred to a hospital for evaluation. Management protocols include the administration of the specific antidote N -acetylcysteine for Paracetamol toxicity, which is maximally protective when given within the first eight hours. Treatment is otherwise symptomatic and supportive, with mandated monitoring of plasma Paracetamol concentration and hepatic function. The Dicyclomine component is associated with severe risks in infants under six months of age, a population for whom its use is contraindicated according to official labeling.

Therapeutic Uses of Tormina

What Tormina Treats: Main Uses and Benefits

Tormina is a prescription medication used to manage specific types of pain and discomfort caused by muscle spasms in certain organs. It may be an important option for patients seeking relief from conditions that involve involuntary muscle contractions.

Therapeutic Domains

  • Intestinal and Abdominal Discomfort: Tormina is used to relieve symptoms of spasmodic pain associated with the gastrointestinal tract, including intestinal colic and general abdominal cramping. It may help reduce the severity of pain and spasms linked to digestive disorders.
  • Irritable Bowel Syndrome (IBS): This medication is indicated for the temporary management of symptoms related to Irritable Bowel Syndrome, particularly the cramping and pain in the lower abdomen.
  • Spasmodic Conditions: The treatment is appropriate for other conditions involving painful spasms, such as discomfort due to biliary colic (gallbladder) and renal colic (kidney stones).
  • Menstrual Pain: Tormina may be prescribed to support relief from spasmodic dysmenorrhea (painful, irregular periods) by addressing the muscular contractions that contribute to the discomfort.

This medication is part of a comprehensive treatment plan to support the management of symptoms and may lead to an improved quality of life when used as directed by a healthcare professional.

Quick Facts

  • Treats: Spasmodic pain and discomfort.
  • Key Uses: Intestinal colic, renal colic, and biliary colic.
  • Additional Use: May help relieve symptoms of spasmodic dysmenorrhea.
  • Focus: Supports the management of discomfort related to muscle spasms.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who can and cannot use Tormina?

Tormina (Dicyclomine/Paracetamol) is subject to strict population eligibility requirements defined by regulatory authorities. Use is generally established for adult patients.

Absolute Contraindications

This medication is contraindicated and must not be used by specific populations, primarily due to the Dicyclomine component's anticholinergic effects or risks associated with Paracetamol:

  • Infants under 6 months of age.
  • Breastfeeding women.
  • Patients with Glaucoma or Myasthenia Gravis.
  • Patients with Obstructive Gastrointestinal Disease, Obstructive Uropathy, or Severe Ulcerative Colitis.
  • Patients with known Hypersensitivity to either active ingredient.

Restrictions and Special Considerations

Use is restricted and often not recommended in several populations:

  • Severe Organ Impairment: Patients with severe hepatic impairment or severe renal impairment.
  • Pregnancy: Use is generally not recommended during the third trimester.
  • Geriatric Patients: Caution is required for older adults due to increased susceptibility to anticholinergic effects.
  • Cardiovascular Conditions: Caution is necessary for patients with conditions such as Coronary Heart Disease or Tachycardia.

What should I know about interactions with other medicines?

Tormina Interactions with other medicines and products

Category
Interacting Substances and Classes
Anticholinergic Agents, Opioid Analgesics, Antacids, Liver Enzyme Inducers, Prokinetic Agents (Metoclopramide/Domperidone), Oral Anticoagulants (Warfarin), Bile Acid Sequestrants, Alcohol.

Official Interaction Statements

  • Formal Prohibition: Co-administration with Pramlintide is formally classified as contraindicated due to documented synergistic inhibition of gastrointestinal (GI) motility.
  • Pharmacodynamic Reinforcement: Combining this medicine with other anticholinergic agents (e.g., Tricyclic Antidepressants, some Antihistamines) or Opioid Analgesics is noted for additive effects that increase the risk of severe constipation or urinary retention.
  • Metabolic Toxicity Risk: Concomitant use with Alcohol or Liver Enzyme Inducers (e.g., Rifampicin, Carbamazepine) is officially stated to potentially increase the formation of a toxic metabolite of the Paracetamol component, which can affect hepatotoxicity risk.
  • Clearance and Exposure: Probenecid is documented to reduce the clearance of the Paracetamol component. Conversely, the Dicyclomine component may increase the systemic exposure of slowly dissolving Digoxin due to slowed GI transit time.
  • Absorption and Timing Rules: Administration of Antacids must be separated by at least 2 hours from Dicyclomine to limit interference with absorption. The absorption of Paracetamol is reduced if Cholestyramine is administered within 1 hour of the dose.
  • Anticoagulant Effect: Prolonged, regular daily use of the Paracetamol component is documented to enhance the anticoagulant effect of Warfarin and other oral anticoagulants.

Population-Specific Interaction Notes

The regulatory label indicates that the Geriatric Population may have increased susceptibility to certain anticholinergic effects when co-administered with interacting agents. Furthermore, the severity of interaction and toxicity risk is heightened in patients with Severe Hepatic or Renal Impairment.

The regulatory documents define Tormina's interaction structure through two distinct component profiles: Dicyclomine imposes restrictions based on additive pharmacodynamic effects and absorption interference. The Paracetamol component drives constraints via its metabolic profile, requiring caution with enzyme inducers and substances that reduce clearance. This dual-component interaction profile results in both formal prohibitions and timing constraints documented in official labeling.

Mechanism of Action

The drug's mechanism is defined by the coordinated action of its two components across peripheral and central physiological systems. The antispasmodic component, Dicyclomine, acts as an antagonist at muscarinic acetylcholine receptors ( M1, M2, M3) in the visceral smooth muscle. By blocking acetylcholine, the drug interrupts signals from the parasympathetic nervous system that drive involuntary contractions, resulting in the physiological consequence of smooth muscle relaxation and a decrease in contractility.

The analgesic component, Paracetamol, is a central mechanism targeting the Cyclooxygenase (COX) enzyme system primarily within the Central Nervous System (CNS). Inhibiting central COX activity limits the synthesis of Prostaglandin E2 ( PGE2), a mediator that enhances nociceptive signaling. This modifies the way the CNS modulates nociceptive signals, leading to the physiological effect of decreased nociceptive signal perception.

This is a synergistic dual action: Dicyclomine acts peripherally to decrease muscle contractility and tone, while Paracetamol acts centrally to modulate the CNS's nociceptive signaling, resulting in a coordinated physiological change.

Dosage and Administration Information

How Tormina is Used: Official Administration Guidelines

This section outlines the administration instructions for the use of the Dicyclomine/Paracetamol combination medicine (Tormina). These guidelines focus on the standard methods for taking the medication as established by pharmacological profiles.

Administration Protocol

Usage Entity Official Instruction
Route of Administration Oral (by mouth).
Approved Form Oral Tablet (Typically 20 mg Dicyclomine / 500 mg Paracetamol).
Intake Condition May be taken with or without food.
Preparation Tablets must be swallowed whole; they should not be crushed, chewed, or broken.

Standard Dosing and Duration

Tormina is typically prescribed for short-term use. The regimen for adults is structured around the antispasmodic component, Dicyclomine, and is focused on establishing an effective dose promptly.

  • Standard Adult Dose: One tablet, or Dicyclomine 20 mg, taken four times a day (QID).
  • Dose Escalation: Dosing may be increased up to a maximum Dicyclomine dose of 40 mg four times a day (160 mg total daily). This is done under medical supervision.
  • Maximum Daily Dose: The total dose of the Dicyclomine component must not exceed 160 mg per 24 hours.

Time Constraints and Use in Specific Groups

There are specific time constraints and considerations for treatment evaluation:

  • Treatment Duration: If the medication fails to provide adequate symptomatic relief, or if side effects limit the dose to less than 80 mg per day, the drug should be discontinued after two weeks. Documented safety data for doses above 80 mg daily are generally not available for periods longer than two weeks.
  • Pediatric Use: Tormina is not recommended for use in children under 12 years of age.
  • Older Adults: Caution is advised, as the geriatric population may be more sensitive to the effects of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tormina

Research Evidence for Symptom Management in Irritable Bowel Syndrome (IBS)

Research has studied the components of Tormina in the context of Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating or episodic manifestations of pain and cramping. The primary component, Dicyclomine, was evaluated in studies, including short-term Randomized Controlled Trials (RCTs), used in research exploring symptom patterns. These studies examined outcomes related to patient-reported outcomes describing perceived discomfort, specifically focusing on abdominal pain intensity and outcomes related to spasm or cramping.

Findings describe patterns observed in the studies where participants experienced changes in their reported levels of abdominal pain and spasm frequency over the short observation periods. Research indicates that the focus of studies was primarily on short-term symptom patterns of these acute symptoms. The studies contribute to the broader evidence landscape by providing insight into short-term changes associated with the component studied for antispasmodic action.

Research Evidence for Acute Spasmodic Dysmenorrhea (Menstrual Pain)

Tormina was studied for use in acute spasmodic dysmenorrhea, which is a condition associated with acute or disruptive episodes of menstrual cramping. The research examined outcomes related to episodic or acute changes in pain and cramp severity, often measured using established pain scales and patient assessments of perceived discomfort. These studies were often short-term clinical trials focusing on episodes where symptoms become more noticeable.

Long-term effects are not fully established, as the studies were focused entirely on patterns related to acute pain symptoms for a single episode. Therefore, data are still emerging for the use of the FDC beyond the immediate symptomatic event.

Research Evidence for Other Acute Spasmodic Conditions

Research has evaluated the combination for other conditions involving periods of heightened symptoms such as intestinal, biliary, and renal colic. Studies monitored outcomes related to physical discomfort and the need for additional symptomatic measures in emergency settings. Data show patterns related to observed changes in outcomes describing episodic or acute changes in pain measurements over very short periods.

Areas Where Research Remains Uncertain

The available evidence highlights what is known — and what is still uncertain. Comparative evidence is lacking for the specific Tormina combination against all other standard treatments for spasmodic pain. Furthermore, evidence quality varies across studies, and the interpretation of some findings is limited by modest sample sizes.

Key Studies & References

  1. WHO Model List of Essential Medicines (23rd edition) - Paracetamol entry

Frequently Asked Questions (FAQ)

Common questions about Tormina (FAQ)

Q: Is Tormina an anti-inflammatory drug?

Official product information describes Tormina as an Antispasmodic-Analgesic Combination. The Paracetamol component is primarily classified as a pain and fever reducer (analgesic and antipyretic). Regulatory guidance indicates that Paracetamol has only weak anti-inflammatory properties and is not primarily used for that action.

Q: How quickly does Tormina start working?

According to studies, the Paracetamol component of Tormina typically begins to act within 30 minutes after taking it by mouth. The primary regulatory documents do not consistently provide an exact combined onset time for the dual Dicyclomine/Paracetamol formulation.

Q: How long does the effect of Tormina last?

Official regulatory summaries indicate that the effects of the Paracetamol component usually last 4 to 6 hours, which corresponds to the typical dosing interval. The duration of the Dicyclomine component is less formally stated in hours but is associated with the official four-times-daily schedule.

Q: Can I take Tormina if I also take supplements like Vitamin D or magnesium?

Official documents list interactions with specific drug classes and substances, but common vitamin or mineral supplements such as Vitamin D or magnesium are not typically listed. Official patient information generally stresses the importance of disclosing all vitamins, minerals, and herbal products being taken to a healthcare provider.

Q: Is it safe to drive after taking Tormina?

Regulatory labeling includes a formal warning that this medicine may cause effects such as drowsiness, dizziness, or blurred vision. Regulatory documents contain specific warnings about avoiding activities that require high mental alertness, such as driving or operating heavy machinery, if effects like drowsiness or dizziness occur.

Q: What should I do if I miss a scheduled dose of Tormina?

Official patient information addresses what to do if a dose is missed by providing specific guidance on skipping the missed dose and returning to the regular schedule. This detailed guidance is found within the administration sections of the official documents.

Q: Is Tormina a controlled substance?

The Dicyclomine component of Tormina is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA). However, this drug is only available with a prescription from a healthcare provider.

Q: Is Tormina known to interact with caffeine?

Primary regulatory documents do not list a specific interaction with plain caffeine. Paracetamol is sometimes studied or combined with caffeine to enhance its pain-relieving effects. The Dicyclomine component has the potential for increased central nervous system (CNS) effects, such as drowsiness, and the label notes this possibility.

Q: Is Tormina available over the counter?

According to the FDA and other regulatory labels, Tormina, containing Dicyclomine, is designated as a prescription-only drug (Rx). It is not available for purchase over the counter.

Q: Is Tormina known to interact with herbal remedies?

Specific interactions between Tormina and most individual herbal products are not usually detailed in the primary drug regulatory documents. Official patient materials frequently state that a complete list of all medications, including all herbal remedies and supplements, should be disclosed to a healthcare provider.

Q: Does Tormina have a black box warning from regulatory agencies?

The official FDA prescribing information for Dicyclomine, a component of Tormina, does not require the specific designation of a Black Box Warning. However, the labeling does contain strong Warnings and Precautions regarding risks in certain patient groups and severe adverse reactions.

Q: Does Tormina affect fertility?

Regulatory guidance related to the Paracetamol component suggests that studies have not established evidence indicating a reduction in fertility in men or women. Information concerning the effect of the Dicyclomine component on fertility is not routinely or prominently provided in the primary regulatory summaries.

Q: Is Tormina a brand name or a generic drug?

Tormina is a potential brand name used for this fixed-dose combination. The active components, Dicyclomine (also known as Dicycloverine) and Paracetamol, are both widely available as FDA-approved generic medications.

How should Tormina be stored and disposed of?

How to Store and Dispose of Tormina?

Requirement Official Instructions
Storage Temperature Store at controlled room temperature, typically 20 C to 25 C, or below 30 C [1.1, 3.7].
Environmental Protection Protect the tablets from excessive heat, moisture, and direct light. Do not store in a damp place or in areas prone to heat fluctuations [1.1, 3.7].
Packaging Keep the medicine in the original container or pack and ensure the container is tightly closed [3.1].
Child Safety It is mandatory to keep this medicine out of the sight and reach of children and pets to prevent accidental ingestion [3.5, 3.7].
Disposal Do not dispose of unused or expired medicine via wastewater or household waste. Consult a pharmacist or utilize a drug take-back program if available. If disposal at home is necessary, mix the medicine with an undesirable substance like dirt or cat litter, place it in a sealed bag, and throw it in the household trash, in line with regulatory guidelines [2.1, 2.6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tormina found in:

A-Z Index: